Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 230

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 230
---
 its regularly scheduled meetings or during an open - 159 -

trading window. Although equity awards are sometimes granted off-cycleor during closed trading windows, typically stock options approved at such time become effective during an open window. We have not granted, nor do we intend to grant, stock options in anticipation of the release of material, nonpublic information that is likely to result in changes to the price of our common stock, such as a significant positive or negative earnings announcement, and, we have not taken, nor do we intend to take, material nonpublic information into account when determining the terms of stock options. Similarly, we have not timed, nor do we intend to time, the release of material, nonpublic information for the purpose of affecting the value of executive compensation or for any other purpose. Overview Our executive compensation program reflects our growth and corporate goals. To date, the compensation of the named executive officers has consisted of a combination of base salary, annual cash bonus, and long-term equity incentive compensation in the form of restricted stock and stock options, and other employee benefits generally available to our employees. The named executive officers are also entitled to compensation and benefits upon certain terminations of employment pursuant to their executive employment agreements as described below. The named executive officers for the year ended December 31, 2024 were as follows:

| • |     | David Lennon, Ph.D., our President and Chief Executive Officer; |

| • |     | Scott Giacobello, our Chief Financial Officer; |

| • |     | Bryan Ball, our Chief Technical Operations Officer. |

| • |     | Neil Desai, Ph.D., our former Executive Chairman; and |

| • |     | Loretta Itri, M.D., our former Chief Medical Officer. |

- 160 -

Summary Compensation Table The following table sets forth information regarding compensation awarded to, earned by or paid to each of the named executive officers for the years ended December 31, 2024 and 2023. The total compensation presented does not reflect the actual compensation received by our named executive officers. For example, the amounts in the “Stock Awards” column include the grant date fair values of time-based restricted stock units granted in that applicable year and the amounts in the “Option Awards” column include the grant date fair values of time-based stock options granted in that applicable year.

| Name and Principal Position                                                      |     | Year |      |     | Salary 
 ($)    |         |     | Option 
 Awards 
 ($)(1) |           |     |